MRKR News and Press, Marker Therapeutics Inc. From 08/28/25

HOUSTON, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that ...

2025-08-26 09:42:44 ET DENVER, Colo., Aug 26, 2025 ( 247marketnews.com )- Biotechs are lighting up the tape. Allarity Therapeutics (NASDAQ:ALLR) is charging ahead after announcing FDA Fast Track designation for its dual PARP/WNT inhibitor stenoparib in advanced ovarian cancer. T...

2025-08-26 08:03:41 ET DENVER, Colo., Aug 26, 2025 ( 247marketnews.com )- Marker Therapeutics (NASDAQ:MRKR) reported encouraging interim results from its ongoing Phase 1 APOLLO study of MT-601, a novel Multi-Antigen Recognizing T cell (MAR-T) therapy for relapsed B cell lymphoma. Am...

Ongoing Phase 1 APOLLO study investigating MT-601 in patients with relapsed B cell lymphoma showed 66% of Non-Hodgkin Lymphoma (NHL) patients achieving objective response rates, with 50% demonstrating complete response (CR) Favorable safety profile observed in study participants with ...

Western Uranium & Vanadium Corp (WSTRF) is expected to report for Q2 2025 IceCure Medical Ltd. (ICCM) is expected to report $-0.06 for Q2 2025 TFF Pharmaceuticals Inc - Ordinary Shares (TFFP) is expected to report for quarter end 2025-06-30 Scientific Industries, Inc. (SCND) is ex...

Marker Therapeutics Inc. (MRKR) is expected to report $-0.55 for Q2 2025

HOUSTON, July 30, 2025 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that ...

HOUSTON, June 17, 2025 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced a collabor...

2025-05-20 18:47:55 ET Marker Therapeutics, Inc. (MRKR) - This analysis reviews how the stock price reacted during the last 12 earnings periods. The average open to high on the day of earnings was 3.40%. The average open to low on the day of earnings was -7.77%. The average open...

2025-05-20 18:42:55 ET Marker Therapeutics, Inc. (MRKR) - Following Earnings Price Analysis was done using last 12 quarters historical earnings. Opening Gap Moves The historical opening gap move in MRKR stock price following earnings has averaged ±2.89% , with a median of 2.63%...